Durvalumab immune checkpoint inhibition

Imfinzi - durvalumab      

pdf
pathology Demonstrated benefit and harm k      
lung cancer (metastatic)

versus

No demonstrated result for efficacy

1 trialmeta-analysis
lung cancer (metastatic)

versus placebo

durvalumab superior to placebo in terms of PFS in PACIFIC, 2017 (maintenance patients)

1 trialmeta-analysis
urothelial carcinoma (advanced)

versus

No demonstrated result for efficacy

1 trialmeta-analysis